NICE recommends Merck Pembrolizumab for advanced melanoma

NICE recommends Merck Pembrolizumab for advanced melanoma

October 14, 2015 Source: Lilac Garden

Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];

                           
The National Institute for Health Care Optimization (NICE) recommended Merck's Keytruda (pembrolizumab) for the treatment of advanced melanoma previously treated with ipilimumab. NICE recommends the use of Pembrolizumab as a therapeutic drug in NHS for patients with advanced, unresectable or metastatic melanoma.

Pembrolizumab has been marketed in the UK as a monotherapy for advanced (unremovable or metastatic) melanoma adult patients. This indication is more extensive than the indications covered in this assessment, as this assessment was limited to Pembrolizumab for patients who had previously been treated with ipilimumab.

Pembrolizumab is recommended for use with patients who have progressed with ipilimumab and with a BRAF or MEK inhibitor (for BRAF V600 mutation-positive disease); according to the patient acquisition plan, the company provides Pembrolizumab through a discount.

Pembrolizumab is the first drug approved through an early drug acquisition program

Pembrolizumab is the first drug approved through the Early Access to Medicines Program (EAMS) of the Drug and Healthcare Products Regulatory Authority. The program is designed to allow patients with life-threatening or severely debilitating diseases to obtain drugs that are not yet licensed for marketing when there is a clear lack of medical needs.

Professor Longson, Director of the NICE Health Technology Evaluation Center, said, “We are very pleased to recommend Pembrolizumab in the final guide, which was the first drug approved through the Early Access to Drugs Program of the Drug and Healthcare Products Regulatory Authority. In 2011, there were over 1.3 in the UK. Tens of thousands of people have been diagnosed with malignant melanoma, and melanoma causes more deaths than all other skin cancers. This is a welcome news for patients and health care professionals."

The Secretary of Life Sciences, Mr. George Freeman, said, "This is good news for thousands of patients diagnosed with malignant melanoma each year because they can now use this life-enhancing drug for treatment."

The National Institute for Health Care Optimization (NICE) recommended Merck's Keytruda (pembrolizumab) for the treatment of advanced melanoma previously treated with ipilimumab. NICE recommends the use of Pembrolizumab as a therapeutic drug in NHS for patients with advanced, unresectable or metastatic melanoma.

Pembrolizumab has been marketed in the UK as a monotherapy for advanced (unremovable or metastatic) melanoma adult patients. This indication is more extensive than the indications covered in this assessment, as this assessment was limited to Pembrolizumab for patients who had previously been treated with ipilimumab.

Pembrolizumab is recommended for use with patients who have progressed with ipilimumab and with a BRAF or MEK inhibitor (for BRAF V600 mutation-positive disease); according to the patient acquisition plan, the company provides Pembrolizumab through a discount.

Pembrolizumab is the first drug approved through an early drug acquisition program

Pembrolizumab is the first drug approved through the Early Access to Medicines Program (EAMS) of the Drug and Healthcare Products Regulatory Authority. The program is designed to allow patients with life-threatening or severely debilitating diseases to obtain drugs that are not yet licensed for marketing when there is a clear lack of medical needs.

Professor Longson, Director of the NICE Health Technology Evaluation Center, said, “We are very pleased to recommend Pembrolizumab in the final guide, which was the first drug approved through the Early Access to Drugs Program of the Drug and Healthcare Products Regulatory Authority. In 2011, there were over 1.3 in the UK. Tens of thousands of people have been diagnosed with malignant melanoma, and melanoma causes more deaths than all other skin cancers. This is a welcome news for patients and health care professionals."

The Secretary of Life Sciences, Mr. George Freeman, said, "This is good news for thousands of patients diagnosed with malignant melanoma each year because they can now use this life-enhancing drug for treatment."

FFP2 Masks For Virus Protection

Product Dimesnion: 6.18" x 4.13" /15.70cmx10.50cm

Mask Fabric Material: 5-ply material,100% polypropelyne

Ear Loop Material: 70% polyamide, 30% elastane

when to use: suitable for adults to use daily in a variety of settings such as home, outdoors and work

packaging: 5 pcs of mask in one sealed printed plastic bag to ensure hygiene or 10pcs per box

certification/standard: EN149:2001+A1:2009 and CE Mark

about the manufacturer: Kapanou is china-based healthcare company

FFP2 Masks are Available,FFP2 Mask Reusable,FFP2 Face Mask,FFP2 Face Masks For Virus Protection,FFP2 Mask for Sale

Ningbo Debeida Science&Technology Co.,ltd. , https://www.dbdmask.com